263 related articles for article (PubMed ID: 27311730)
1. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Shih KC; Chowdhary S; Rosenblatt P; Weir AB; Shepard GC; Williams JT; Shastry M; Burris HA; Hainsworth JD
J Neurooncol; 2016 Sep; 129(2):281-8. PubMed ID: 27311730
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
4. IFN-α for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series.
Chamberlain MC
CNS Oncol; 2013 May; 2(3):227-35. PubMed ID: 25054463
[TBL] [Abstract][Full Text] [Related]
5. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
[TBL] [Abstract][Full Text] [Related]
6. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
Gorsi HS; Khanna PC; Tumblin M; Yeh-Nayre L; Milburn M; Elster JD; Crawford JR
Pediatr Blood Cancer; 2018 Sep; 65(9):e27234. PubMed ID: 29750399
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
[TBL] [Abstract][Full Text] [Related]
9. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
10. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T.
Tsimafeyeu I; Snegovoy A; Varlamov S; Safina S; Varlamov I; Gurina L; Manzuk L
Target Oncol; 2015 Sep; 10(3):423-7. PubMed ID: 25466382
[TBL] [Abstract][Full Text] [Related]
12. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute.
Yardley DA; Bosserman LD; O'Shaughnessy JA; Harwin WN; Morgan SK; Priego VM; Peacock NW; Bass JD; Burris HA; Hainsworth JD
Breast Cancer Res Treat; 2015 Nov; 154(1):89-97. PubMed ID: 26456573
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma.
Phuphanich S; Raizer J; Chamberlain M; Canelos P; Narwal R; Hong S; Miday R; Nade M; Laubscher K
J Neurooncol; 2017 Jan; 131(1):185-191. PubMed ID: 27844311
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
Chamberlain MC; Glantz MJ
Cancer; 2008 Oct; 113(8):2146-51. PubMed ID: 18756531
[TBL] [Abstract][Full Text] [Related]
16. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib.
Cardona AF; Ruiz-Patiño A; Zatarain-Barrón ZL; Hakim F; Jiménez E; Mejía JA; Ramón JF; Useche N; Bermúdez S; Pineda D; Cifuentes H; Rojas L; Ricaurte L; Pino LE; Balaña C; Arrieta O
PLoS One; 2019; 14(6):e0217340. PubMed ID: 31220093
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma.
Chamberlain MC
J Neurooncol; 2012 Apr; 107(2):315-21. PubMed ID: 22127733
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Raizer JJ; Grimm SA; Rademaker A; Chandler JP; Muro K; Helenowski I; Rice L; McCarthy K; Johnston SK; Mrugala MM; Chamberlain M
J Neurooncol; 2014 Mar; 117(1):93-101. PubMed ID: 24449400
[TBL] [Abstract][Full Text] [Related]
19. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma.
Kumthekar P; Grimm SA; Aleman RT; Chamberlain MC; Schiff D; Wen PY; Iwamoto FM; Gursel DB; Reardon DA; Purow B; Kocherginski M; Helenowski I; Raizer JJ
Neurooncol Adv; 2022; 4(1):vdac123. PubMed ID: 36225651
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in Recurrent High-Grade Gliomas: A Canadian Retrospective Study.
Lim Fat MJ; Maurice C; Maganti M; Mason WP
Can J Neurol Sci; 2018 Jan; 45(1):56-61. PubMed ID: 29151389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
